Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
Other Sizes |
|
ln Vitro |
When co-cultured with macrophages, MG63 cells are reduced in number by mifamotide sodium (MTP-PE sodium; 100 µM) [3]. The M1 polarization marker iNOS and the M2 polarization marker CD206 mRNA, as well as pro- and anti-inflammatory cytokines (IL-1β, IL-6) and IL-4, IL-10), are increased by mifamotide sodium (100 µM). The iron transporter DMT1 protein can be increased by mifamotide sodium [3]. The two osteosarcoma cell lines MOS-J and KHOS do not exhibit a direct response to L-mifamutide sodium (5, 5000 nM; 48 hours of action) when it is used alone [1]. Mifamotide sodium is a non-specific immunomodulator that activates macrophages and monocytes to increase tumoricidal activity and release pro-inflammatory cytokines, such as interleukin (IL) and tumor necrosis factor (TNF)-a. )-1, prostaglandin E2 (PGE2), IL-6, IL-8, IL-12, nitric oxide (NO), and PGD2[3].
|
---|---|
ln Vivo |
The administration of 1 mg/kg of mifamotide sodium (MTP-PE sodium) intravenously twice a week for 4 weeks tends to inhibit the spread of spontaneous pulmonary metastases [1]. In mice with endotoxemia, mifamotide sodium (50 μg/mouse) enhances glucose tolerance. Without affecting body weight, mifamotide sodium (equal to 20 μg MDP) increases glucose tolerance in HFD-fed rats when administered four times a week for five weeks [2].
|
Animal Protocol |
Animal/Disease Models: C57BL/6, balb/c (Bagg ALBino) mouse with KHOS osteosarcoma cells [1]
Doses: 1 mg/kg Route of Administration: IV; twice weekly for 4 weeks Experimental Results: Results in xenogeneic (KHOS) and Trend toward diminished spread of spontaneous lung metastases in a syngeneic (MOS-J) model. |
References |
[1]. Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89.
[2]. Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3. [3]. Francesca Punzo, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020 Feb 18;11(7):687-698. |
Molecular Formula |
C59H108N6NAO19P
|
---|---|
Molecular Weight |
1259.49
|
Exact Mass |
1258.7305
|
CAS # |
90825-43-7
|
Related CAS # |
Mifamurtide;83461-56-7;Mifamurtide TFA;Mifamurtide sodium hydrate;838853-48-8
|
SMILES |
[C@@]([H])([C@H](O)[C@H](O)CO)(O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(=O)N)CCC(=O)N[C@@H](C)C(=O)NCCOP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@H](C=O)NC(=O)C.[NaH]
|
Synonyms |
L-MTP-PE; CGP 19835A; Mifamurtide sodium
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~50 mg/mL (~39.70 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (3.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (3.97 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (3.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7940 mL | 3.9699 mL | 7.9397 mL | |
5 mM | 0.1588 mL | 0.7940 mL | 1.5879 mL | |
10 mM | 0.0794 mL | 0.3970 mL | 0.7940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.